Effect of Cry-consensus Peptide, a Novel Recombinant Peptide for Immunotherapy of Japanese Cedar Pollinosis, on an Experimental Allergic Rhinitis Model in B10.S Mice
Open Access
- 1 January 2007
- journal article
- Published by Japanese Society of Allergology in Allergology International
- Vol. 56 (4), 465-472
- https://doi.org/10.2332/allergolint.o-07-495
Abstract
We are developing an immunotherapeutic peptide, Cry-consensus peptide, for Japanese cedar pollinosis. Cry-consensus peptide is a recombinant polypeptide containing six major human T-cell epitopes derived from both Cry j 1 and Cry j 2, two major allergens of Japanese cedar pollen. We examined the effect of Cry-consensus peptide on an allergic rhinitis model in B10.S mice, which have one common T-cell epitope in the Cry-consensus peptide.B10.S mice were sensitized with Cry j 1/alum, then the Cry-consensus peptide was administered subcutaneously once a week for 5 weeks from the last sensitization. Histamine was dropped in both nostrils (10 microL per nostril) of each mouse on the day before continuous intranasal instillation of Cry j 1. Soon after the final challenge with Cry j 1, the mice were observed for 5 minutes for the resulting number of sneezes. In addition, serum levels of Cry j 1-specific IgE and IgG2a antibody, eosinophil infiltration in nasal tissue, and Cry j 1-specific cytokine production from splenocytes were evaluated.Cry-consensus peptide markedly inhibited Cry j 1-induced sneezes, eosinophil infiltration, and eosinophil peroxidase (EPO) activity in nasal tissue. Cry-consensus peptide inhibited the production of anti-Cry j 1 IgE (Th2-mediated) and significantly enhanced anti-Cry j 1 IgG2a (Th1-mediated). In cytokine production from splenocytes, Cry-consensus peptide significantly decreased in IL-4/IFN-gamma and IL-5/IFN-gamma ratios.It was concluded that Cry-consensus peptide effectively controlled allergic responses, which results from shifting from a Th2-dominated to a Th1-dominated immune response.Keywords
This publication has 27 references indexed in Scilit:
- Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled studyAllergologia et Immunopathologia, 2006
- Specific immunotherapy – an optimistic futureAllergy, 2006
- The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitisPediatric Allergy and Immunology, 2006
- Eosinophil infiltration of the oesophageal mucosa in patients with pollen allergy during the seasonClinical and Experimental Allergy, 2005
- Non‐anaphylactic surface‐exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccinationClinical and Experimental Allergy, 2004
- Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response☆Journal of Allergy and Clinical Immunology, 2004
- Epidemiology of Japanese cedar pollinosis throughout JapanAnnals of Allergy, Asthma & Immunology, 2003
- C8/119S Mutation of Major Mite Allergen Derf-2 Leads to Degenerate Secondary Structure and Molecular Polymerization and Induces Potent and Exclusive Th1 Cell DifferentiationThe Journal of Immunology, 2000
- Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998
- Sensitivity to two major allergens (Cry j I and Cry j II) in patients with Japanese cedar (Cryptomeria japonica) pollinosisClinical and Experimental Allergy, 1995